GLUE
Monte Rosa Therapeutics, Inc.
Biotechnology
Market Cap$1.11B
5Y Perf.-19.7%
Build Your Comparison
Side-by-side financial analysisGLUE
KYMR
JPM
Try popular comparisons:
Stock Comparison
GLUE vs KYMR vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$6.77B
5Y Perf.+77.7%
JPM
JPMorgan Chase & Co.
Banks - Diversified
Market Cap$875.80B
5Y Perf.+106.2%
GLUE vs KYMR vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  GLUE |  KYMR |  JPM |
|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Banks - Diversified |
| Market Cap | $1.11B | $6.77B | $875.80B |
| Revenue (TTM) | $43M | $51M | $280.33B |
| Net Income (TTM) | $-130M | $-315M | $57.05B |
| Gross Margin | 95.3% | 33.2% | 60.0% |
| Operating Margin | -345.2% | -7.0% | 25.9% |
| Forward P/E | — | — | 14.1x |
| Total Debt | $39M | $82M | $942.38B |
| Cash & Equiv. | $130M | $357M | $343.34B |
GLUE vs KYMR vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GLUE
KYMR
JPM
| Stock | Jun 21 | Jun 26 | Return |
|---|---|---|---|
| Monte Rosa Therapeu… (GLUE) | 100 | 80.3 | -19.7% |
| Kymera Therapeutics… (KYMR) | 100 | 177.7 | +77.7% |
| JPMorgan Chase & Co. (JPM) | 100 | 206.2 | +106.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GLUE vs KYMR vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JPM leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. Monte Rosa Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
GLUE
Monte Rosa Therapeutics, Inc.
The Growth Play
GLUE is the clearest fit if your priority is growth exposure.
- Rev growth 63.5%, EPS growth 53.1%
- 63.5% revenue growth vs KYMR's -16.7%
- +238.6% vs JPM's +19.1%
Best for: growth exposure
KYMR
Kymera Therapeutics, Inc.
The Income Pick
KYMR is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.90
- Lower volatility, beta 0.90, Low D/E 5.2%, current ratio 10.47x
- Beta 0.90, current ratio 10.47x
Best for: income & stability and sleep-well-at-night
JPM
JPMorgan Chase & Co.
The Banking Pick
JPM carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 454.4% 10Y total return vs KYMR's 149.4%
- 20.4% margin vs KYMR's -6.1%
- 1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  GLUE | 63.5% revenue growth vs KYMR's -16.7% |
| Quality / Margins |  JPM | 20.4% margin vs KYMR's -6.1% |
| Stability / Safety |  KYMR | Beta 0.90 vs GLUE's 1.30, lower leverage |
| Dividends | JPM | 1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend |
| Momentum (1Y) | GLUE | +238.6% vs JPM's +19.1% |
| Efficiency (ROA) | JPM | 1.3% ROA vs GLUE's -25.9%, ROIC 4.5% vs -44.2% |
GLUE vs KYMR vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
GLUE vs KYMR vs JPM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJPMLAGGINGGLUE
GLUEMonte Rosa Therapeuti…
0leads
KYMRKymera Therapeutics, …
1leads
JPMJPMorgan Chase & Co.
3leads
6 Total Categories
CATEGORYLEADERvs KYMRvs GLUEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JPM4/6
Valuation MetricsMultiples, price ratios, and targets
JPM2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
JPM5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
KYMR3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 6526.5x GLUE's $43M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to KYMR's -6.1%. On growth, KYMR holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GLUEMonte Rosa Therap… | KYMRKymera Therapeuti… | JPMJPMorgan Chase & … |
|---|---|---|---|
| RevenueTrailing 12 months | $43M | $51M | $280.3B |
| EBITDAEarnings before interest/tax | -$140M | -$352M | $81.4B |
| Net IncomeAfter-tax profit | -$130M | -$315M | $57.0B |
| Free Cash FlowCash after capex | -$20M | -$244M | $100.9B |
| Gross MarginGross profit ÷ Revenue | +95.3% | +33.2% | +60.0% |
| Operating MarginEBIT ÷ Revenue | -3.5% | -7.0% | +25.9% |
| Net MarginNet income ÷ Revenue | -3.0% | -6.1% | +20.4% |
| FCF MarginFCF ÷ Revenue | -45.8% | -4.7% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -95.0% | +55.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +13.4% | +16.0% |
JPM leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
JPM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | GLUEMonte Rosa Therap… | KYMRKymera Therapeuti… | JPMJPMorgan Chase & … |
|---|---|---|---|
| Market CapShares × price | $1.1B | $6.8B | $875.8B |
| Enterprise ValueMkt cap + debt − cash | $1.0B | $6.5B | $1.47T |
| Trailing P/EPrice ÷ TTM EPS | -37.17x | -22.48x | 15.64x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 14.08x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.20x |
| EV / EBITDAEnterprise value multiple | — | — | 18.11x |
| Price / SalesMarket cap ÷ Revenue | 9.00x | 172.78x | 3.13x |
| Price / BookPrice ÷ Book value/share | 6.10x | 4.43x | 2.42x |
| Price / FCFMarket cap ÷ FCF | — | — | 8.68x |
JPM leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
JPM leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-41 for GLUE. KYMR carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), GLUE scores 6/9 vs KYMR's 4/9, reflecting solid financial health.
| Metric | GLUEMonte Rosa Therap… | KYMRKymera Therapeuti… | JPMJPMorgan Chase & … |
|---|---|---|---|
| ROE (TTM)Return on equity | -41.0% | -25.0% | +15.9% |
| ROA (TTM)Return on assets | -25.9% | -22.3% | +1.3% |
| ROICReturn on invested capital | -44.2% | -24.9% | +4.5% |
| ROCEReturn on capital employed | -16.3% | -27.2% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.17x | 0.05x | 2.60x |
| Net DebtTotal debt minus cash | -$91M | -$275M | $599.0B |
| Cash & Equiv.Liquid assets | $130M | $357M | $343.3B |
| Total DebtShort + long-term debt | $39M | $82M | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | — | -2119.53x | 0.74x |
JPM leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
KYMR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $20,999 today (with dividends reinvested), compared to $8,074 for GLUE. Over the past 12 months, GLUE leads with a +238.6% total return vs JPM's +19.1%. The 3-year compound annual growth rate (CAGR) favors KYMR at 48.9% vs JPM's 32.6% — a key indicator of consistent wealth creation.
| Metric | GLUEMonte Rosa Therap… | KYMRKymera Therapeuti… | JPMJPMorgan Chase & … |
|---|---|---|---|
| YTD ReturnYear-to-date | +11.7% | +14.0% | -2.8% |
| 1-Year ReturnPast 12 months | +238.6% | +71.4% | +19.1% |
| 3-Year ReturnCumulative with dividends | +149.6% | +230.0% | +133.1% |
| 5-Year ReturnCumulative with dividends | -19.3% | +64.1% | +110.0% |
| 10-Year ReturnCumulative with dividends | -19.3% | +149.4% | +454.4% |
| CAGR (3Y)Annualised 3-year return | +35.7% | +48.9% | +32.6% |
KYMR leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KYMR and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
KYMR is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than GLUE's 1.30 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 93.0% from its 52-week high vs GLUE's 66.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GLUEMonte Rosa Therap… | KYMRKymera Therapeuti… | JPMJPMorgan Chase & … |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 0.91x | 0.94x |
| 52-Week HighHighest price in past year | $25.77 | $103.00 | $337.25 |
| 52-Week LowLowest price in past year | $4.12 | $36.65 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +66.4% | +80.5% | +93.0% |
| RSI (14)Momentum oscillator 0–100 | 36.4 | 47.7 | 54.8 |
| Avg Volume (50D)Average daily shares traded | 818K | 493K | 7.0M |
Evenly matched — KYMR and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: GLUE as "Buy", KYMR as "Buy", JPM as "Buy". Consensus price targets imply 85.7% upside for GLUE (target: $32) vs 8.1% for JPM (target: $339). JPM is the only dividend payer here at 1.90% yield — a key consideration for income-focused portfolios.
| Metric | GLUEMonte Rosa Therap… | KYMRKymera Therapeuti… | JPMJPMorgan Chase & … |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $31.75 | $112.60 | $338.78 |
| # AnalystsCovering analysts | 9 | 26 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.9% |
| Dividend StreakConsecutive years of raises | — | — | 15 |
| Dividend / ShareAnnual DPS | — | — | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
JPM leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). KYMR leads in 1 (Total Returns). 1 tied.
Best OverallJPMorgan Chase & Co. (JPM)Leads 3 of 6 categories
Loading custom metrics...
GLUE vs KYMR vs JPM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is GLUE or KYMR or JPM a better buy right now?
For growth investors, Monte Rosa Therapeutics, Inc.
(GLUE) is the stronger pick with 63. 5% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Monte Rosa Therapeutics, Inc. (GLUE) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GLUE or KYMR or JPM?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +110. 0%, compared to -19. 3% for Monte Rosa Therapeutics, Inc. (GLUE). Over 10 years, the gap is even starker: JPM returned +465. 8% versus GLUE's -13. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GLUE or KYMR or JPM?
By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.
(KYMR) is the lower-risk stock at 0. 91β versus Monte Rosa Therapeutics, Inc. 's 1. 29β — meaning GLUE is approximately 41% more volatile than KYMR relative to the S&P 500. On balance sheet safety, Kymera Therapeutics, Inc. (KYMR) carries a lower debt/equity ratio of 5% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
04Which is growing faster — GLUE or KYMR or JPM?
By revenue growth (latest reported year), Monte Rosa Therapeutics, Inc.
(GLUE) is pulling ahead at 63. 5% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Monte Rosa Therapeutics, Inc. grew EPS 53. 1% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GLUE or KYMR or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is GLUE or KYMR or JPM more undervalued right now?
Analyst consensus price targets imply the most upside for GLUE: 85.
7% to $31. 75.
07Which pays a better dividend — GLUE or KYMR or JPM?
In this comparison, JPM (1.
9% yield) pays a dividend. GLUE, KYMR do not pay a meaningful dividend and should not be held primarily for income.
08Is GLUE or KYMR or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, GLUE: -13. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between GLUE and KYMR and JPM?
These companies operate in different sectors (GLUE (Healthcare) and KYMR (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: GLUE is a small-cap high-growth stock; KYMR is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while GLUE, KYMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.